Splenomegaly and Oral Terbinafine
Oral terbinafine does not cause splenomegaly (enlarged spleen) as a recognized adverse effect. Splenomegaly is not listed among the documented side effects of terbinafine in either major clinical guidelines or FDA labeling.
Evidence from Drug Labeling and Guidelines
The FDA drug label for oral terbinafine provides comprehensive safety information but does not include splenomegaly among its adverse reactions 1. The documented adverse effects include:
- Most common (from postmarketing surveillance): Gastrointestinal symptoms (49%) such as nausea, diarrhea, and taste disturbance; dermatological events (23%) including rash, pruritus, urticaria, or eczema 2
- Serious but rare: Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatotoxicity (particularly in patients with pre-existing liver disease), and permanent taste disturbance 2
- Hematological: The guidelines recommend baseline complete blood counts in patients with history of hematological abnormalities 2, but this relates to monitoring rather than splenomegaly
The British Association of Dermatologists' 2014 guidelines extensively detail terbinafine's safety profile and make no mention of splenomegaly as an adverse effect 2.
Important Clinical Considerations
When Splenomegaly Occurs During Terbinafine Treatment
If a patient develops splenomegaly while taking terbinafine, look for alternative explanations:
- Drug-induced hepatotoxicity with secondary effects: While terbinafine can rarely cause hepatotoxicity 3, this typically manifests as cholestatic liver injury rather than splenomegaly. However, severe liver injury with portal hypertension could theoretically lead to congestive splenomegaly 4, 5
- Unrelated hematologic conditions: The research literature indicates drug-induced splenomegaly generally results from hemolysis or hepatic disturbances with portal congestion 4, 5
- Coincidental findings: The splenomegaly may be unrelated to terbinafine use
Monitoring Recommendations
Baseline monitoring should include liver function tests and complete blood count in patients with:
- History of heavy alcohol consumption
- Hepatitis or hepatotoxicity
- Hematological abnormalities
- Pediatric patients (as terbinafine is not licensed for pediatric onychomycosis) 2
Contraindications Related to Organ Systems
Terbinafine is contraindicated or requires caution in:
Bottom Line
Splenomegaly is not a recognized adverse effect of oral terbinafine. If splenomegaly develops during terbinafine therapy, investigate other causes including hepatic complications, hematologic disorders, or unrelated conditions. The drug's well-documented adverse effects primarily involve gastrointestinal symptoms, dermatological reactions, and rare but serious hepatotoxicity—none of which typically include splenic enlargement as a direct consequence.